Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹305.20up ₹5.10 (1.70%)BSE ₹305.20
Share price at the NSE close on 28 Oct 2026. Previous close ₹300.10.
28 Oct: open ₹301.10, high ₹308.25, low ₹298.65
52-week range of traded prices to 28 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,831 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.76
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,05,30048.0% delivered
Marksans Pharma board and management
30 filed, newest first.
Jul 2025
Mar 2025
Jul 2024
9 Jul · Management
May 2023
30 May · Management
30 May · Management
Nov 2022
May 2022
Sep 2020
Mar 2020
Jul 2019
Mar 2019
Jan 2019
Dec 2018
Aug 2018
Mar 2018
Jan 2018
Mar 2016
Oct 2013
31 Oct · Management
Board of Directors of the Company at its meeting held on October 31, 2013, appointed Mr. Naresh Balwant Wadhwa as an additional Director of the Company. Mr. Wadhwa will be an independent non-executive director.
Sep 2013
26 Sep · Management
Mr.Seetharama Raju Buddharaju who was appointed a Director of the Company in the casual vacancy caused by the resignation of Mr. M.B. Parikh, has ceased to be a Director as such effective from the date of the Annual General Meeting September 26, 2013. Further, be informed that the Shareholders have, at the Annual General Meeting held on September 26, 2013, appointed Mr. Seetharama Raju Buddharaju as a Director of the Company liable to retire by rotation with effect from September 26, 2013.
Sep 2012
27 Sep · Management
Mr. Ajay S. Joshi, who was appointed a Director of the Company in the casual vacancy caused by the resignation of Mr. Kumar Nair, has ceased to be a Director as such effective from the date of the Annual General Meeting held on September 27, 2012. Further, the Company has at the Annual General Meeting held on September 27, 2012 appointed Mr. Ajay S. Joshi as a Director of the Company liable to retire by rotation with effect from September 27, 2012.
Oct 2011
5 Oct · Management
Mr. M.B Parikh has resigned as a Director of the Company with effect from October 5, 2011.The Board of Directors of the Company has at its Meeting held on October 5, 2011, appointed Mr. Seetharama Raju Buddharaju as a Director of the Company to fill the casual vacancy caused by the resignation of Mr. M.B. Parikh.
Jul 2011
15 Jul · Management
Mr. V. Nagaraj has resigned as Director and Whole-time Director of the Company with effect from June 29, 2011.
May 2011
4 May · Management
Board of Directors of the Company at its meeting held on May 02, 2011, has appointed Mr. Ajoy S. Joshi as a Director (non-executive and independent) of the Company to fill the casual vacancy caused by the resignation of Mr. Kumar Nair effective from May 02, 2011.3 May · Management
Board of Directors of the Company has, at its meeting held on May 02, 2011, appointed Mr. Ajoy S. Joshi as a Director (non-executive and independent) of the Company to fill the casual vacancy caused by the resignation of Mr. Kumar Nair effective from May 02, 2011.
Nov 2010
4 Nov · Management
Mr. Kumar Nair has resigned as a Director of the Company effective from November 02, 2010.
Dec 2007
24 Dec · Management
The Company has received a letter from Mr.Ajay Mittal, intimating his resignation from the Directorship of the Company with effect from 24th December, 2007
Feb 2007
13 Feb · Management
Mr. Atul P. Vyas, has resigned from the Directorship of the Company8 Feb · Management
Dr. A.V. Sharma, has resigned from the Directorship of the Company.